|
1
|
Wang LH, Tsai SY, Cook RG, Beattie WG,
Tsai MJ and O'Malley BW: COUP transcription factor is a member of
the steroid receptor superfamily. Nature. 340:163–166. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai SY and Tsai MJ: Chick ovalbumin
upstream promoter-transcription factors (COUP-TFs): Coming of age.
Endocr Rev. 18:229–240. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Polvani S, Pepe S, Milani S and Galli A:
COUP-TFII in health and disease. Cells. 9:1012019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pereira FA, Tsai MJ and Tsai SY: COUP-TF
orphan nuclear receptors in development and differentiation. Cell
Mol Life Sci. 57:1388–1398. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ashraf UM, Sanchez ER and Kumarasamy S:
COUP-TFII revisited: Its role in metabolic gene regulation.
Steroids. 141:63–69. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pereira FA, Qiu Y, Tsai MJ and Tsai SY:
Chicken ovalbumin upstream promoter transcription factor (COUP-TF):
Expression during mouse embryogenesis. J Steroid Biochem Mol Biol.
53:503–508. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pereira FA, Qiu Y, Zhou G, Tsai MJ and
Tsai SY: The orphan nuclear receptor COUP-TFII is required for
angiogenesis and heart development. Genes Dev. 13:1037–1049. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu SP, Cheng CM, Lanz RB, Wang T, Respress
JL, Ather S, Chen W, Tsai SJ, Wehrens XH, Tsai MJ and Tsai SY:
Atrial identity is determined by a COUP-TFII regulatory network.
Dev Cell. 25:417–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin FJ, You LR, Yu CT, Hsu WH, Tsai MJ and
Tsai SY: Endocardial cushion morphogenesis and coronary vessel
development require chicken ovalbumin upstream
promoter-transcription factor II. Arterioscler Thromb Vasc Biol.
32:e135–e146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ
and Tsai SY: Suppression of Notch signaling by the COUP-TFII
transcription factor regulates vein identity. Nature. 435:98–104.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun SH and Park JI: Recent progress on the
role and molecular mechanism of chicken ovalbumin upstream
promoter-transcription factor II in cancer. J Int Med Res.
48:30000605209192362020. View Article : Google Scholar
|
|
12
|
GBD 2016 Causes of Death Collaborators, .
Global, regional, and national age-sex specific mortality for 264
causes of death, 1980–2016: A systematic analysis for the Global
Burden of Disease Study 2016. Lancet. 390:1151–1210. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kenzik KM, Balentine C, Richman J, Kilgore
M, Bhatia S and Williams GR: New-onset cardiovascular morbidity in
older adults with Stage I to III colorectal cancer. J Clin Oncol.
36:609–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keramida K, Charalampopoulos G,
Filippiadis D, Tsougos E and Farmakis D: Cardiovascular
complications of metastatic colorectal cancer treatment. J
Gastrointest Oncol. 10:797–806. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brown JC, Caan BJ, Prado CM, Weltzien E,
Xiao J, Cespedes Feliciano EM, Kroenke CH and Meyerhardt JA: Body
composition and cardiovascular events in patients with colorectal
cancer: A population-based retrospective cohort study. JAMA Oncol.
5:967–972. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Whelton SP, Berning P, Blumenthal RS,
Marshall CH, Martin SS, Mortensen MB, Blaha MJ and Dzaye O:
Multidisciplinary prevention and management strategies for
colorectal cancer and cardiovascular disease. Eur J Intern Med.
87:3–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qin J, Tsai SY and Tsai MJ: The critical
roles of COUP-TFII in tumor progression and metastasis. Cell
Biosci. 4:582014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kruse SW, Suino-Powell K, Zhou XE,
Kretschman JE, Reynolds R, Vonrhein C, Xu Y, Wang L, Tsai SY, Tsai
MJ and Xu HE: Identification of COUP-TFII orphan nuclear receptor
as a retinoic acid-activated receptor. PLoS Biol. 6:e2272008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin FJ, Chen X, Qin J, Hong YK, Tsai MJ
and Tsai SY: Direct transcriptional regulation of neuropilin-2 by
COUP-TFII modulates multiple steps in murine lymphatic vessel
development. J Clin Invest. 120:1694–1707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin J, Chen X, Xie X, Tsai MJ and Tsai SY:
COUP-TFII regulates tumor growth and metastasis by modulating tumor
angiogenesis. Proc Natl Acad Sci USA. 107:3687–3692. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krishnan V, Elberg G, Tsai MJ and Tsai SY:
Identification of a novel sonic hedgehog response element in the
chicken ovalbumin upstream promoter-transcription factor II
promoter. Mol Endocrinol. 11:1458–1466. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu Y, Krishnan V, Pereira FA, Tsai SY and
Tsai MJ: Chicken ovalbumin upstream promoter-transcription factors
and their regulation. J Steroid Biochem Mol Biol. 56:81–85. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soosaar A, Neuman K, Nornes HO and Neuman
T: Cell type specific regulation of COUP-TFII promoter activity.
FEBS Lett. 39:95–100. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riggs KA, Wickramasinghe NS, Cochrum RK,
Watts MB and Klinge CM: Decreased chicken ovalbumin upstream
promoter transcription factor II expression in tamoxifen-resistant
breast cancer cells. Cancer Res. 66:10188–10198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
More E, Fellner T, Doppelmayr H,
Hauser-Kronberger C, Dandachi N, Obrist P, Sandhofer F and
Paulweber B: Activation of the MAP kinase pathway induces chicken
ovalbumin upstream propter-transcription factor II (COUP-TFII)
expression in human breast cancer cell lines. J Endocrinol.
176:83–94. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rosa A and Brivanlou AH: A regulatory
circuitry comprised of miR-302 and the transcription factors OCT4
and NR2F2 regulates human embryonic stem cell differentiation. EMBO
J. 30:237–248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Petit FG, Salas R, Tsai MJ and Tsai SY:
The regulation of COUP-TFII gene expression by Ets-1 is enhanced by
the steroid receptor co-activators. Mech Age Dev. 125:719–732.
2004. View Article : Google Scholar
|
|
28
|
Fu JL, Hsiao KY, Lee HC, Li WN, Chang N,
Wu MH and Tsai SJ: Suppression of COUP-TFII upregulates angiogenin
and promotes angiogenesis in endometriosis. Hum Reprod.
33:1517–1527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diez H, Fischer A, Winkler A, Hu CJ,
Hatzopoulos AK, Breier G and Gessler M: Hypoxia-mediated activation
of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and
adoption of arterial cell fate. Exp Cell Res. 313:1–9. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruan K, Fang X and Ouyang G: MicroRNAs:
Novel regulators in the hallmarks of human cancer. Cancer Lett.
285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng Q, Wu X, Li F, Ning B, Lu X, Zhang Y,
Pan Y and Guan W: miR-27b inhibits gastric cancer metastasis by
targeting NR2F2. Protein Cell. 8:114–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu S, Wilson KD, Ghosh Z, Han L, Wang Y,
Lan F, Ransohoff KJ, Burridge P and Wu JC: MicroRNA-302 increases
reprogramming efficiency via repression of NR2F2. Stem Cells.
31:259–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang IH, Jeong BC, Hur SW, Choi H, Choi
SH, Ryu JH, Hwang YC and Koh JT: MicroRNA-302a stimulates
osteoblastic differentiation by repressing COUP-TFII expression. J
Cell Physiol. 230:911–921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou B, Song J, Han T, Huang M, Jiang H,
Qiao H, Shi J and Wang Y: MiR-382 inhibits cell growth and invasion
by targeting NR2F2 in colorectal cancer. Mol Carcinog.
55:2260–2267. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang W, Liu J, Qiu J, Fu X, Tang Q, Yang
F, Zhao Z and Wang H: MicroRNA-382 inhibits prostate cancer cell
proliferation and metastasis through targeting COUP-TFII. Oncol
Rep. 36:3707–3715. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin SC, Kao CY, Lee HJ, Creighton CJ,
Ittmann MM, Tsai SJ, Tsai SY and Tsai MJ: Dysregulation of
miRNAs-COUP-TFII -FOXM1-CENPF axis contributes to the metastasis of
prostate cancer. Nat Commun. 7:114182016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jeong BC, Kang IH, Hwang YC, Kim SH and
Koh JT: MicroRNA-194 reciprocally stimulates osteogenesis and
inhibits adipogenesis via regulating COUP-TFII expression. Cell
Death Dis. 5:e15322014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kass SU, Pruss D and Wolffe AP: How does
DNA methylation repress transcription? Trends Genet. 13:444–449.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Momparler RL and Bovenzi V: DNA
methylation and cancer. J Cell Physiol. 183:145–154. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Al-Rayyan N, Litchfield LM, Ivanova MM,
Radde BN, Cheng A, Elbedewy A and Klinge CM: 5-Aza-2-deoxycytidine
and trichostatin A increase COUP-TFII expression in
antiestrogen-resistant breast cancer cell lines. Cancer Lett.
347:139–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Davalos V, Lovell CD, Von Itter R,
Dolgalev I, Agrawal P, Baptiste G, Kahler DJ, Sokolova E, Moran S,
Piqué L, et al: An epigenetic switch controls an alternative NR2F2
isoform that unleashes a metastatic program in melanoma. Nat
Commun. 14:18672023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X, Qin J, Cheng CM, Tsai MJ and Tsai
SY: COUP-TFII is a major regulator of cell cycle and Notch
signaling pathways. Mol Endocrinol. 26:1268–1277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Okamura M, Kudo H, Wakabayyashi K, Tanaka
T, Nonaka A, Uchida A, Tsutsumi S, Sakakibara I, Naito M, Osborne
TF, et al: COUP-TFII acts downstream of Wnt/beta-catenin signal to
silence PPARgamma gene expression and repress adipogenesis. Proc
Natl Acad Sci USA. 106:5819–5824. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Al Turki S, Manickaraj AK, Mercer CL,
Gerety SS, Hitz MP, Lindsay S, D'Alessandro LC, Swaminathan GJ,
Bentham J, Arndt AK, et al: Rare variants in NR2F2 cause congenital
heart defects in humans. Am J Hum Genet. 94:574–585. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sissaoui S, Yu J, Yan A, Li R, Yukselen O,
Kucukural A, Zhu LJ and Lawson ND: Genomic characterization of
endothelial enhancers reveals a multifunctional role for NR2F2 in
regulation of arteriovenous gene expression. Cir Res. 126:875–888.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cui X, Lu YW, Lee V, Kim D, Dorsey T, Wang
Q, Lee Y, Vincent P, Schwarz J and Dai G: Venous endothelial marker
COUP-TFII regulates the distinct pathologic potentials of adult
arteries and veins. Sci Rep. 5:161932015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Adams RH and Alito K: Molecular regulation
of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol.
8:464–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Suri C, Jones PF, Patan S, Bartunkova S,
Maisonpierre PC, Davis S, Sat TN and Yancopoulos GD: Requisite role
for angiopoitin-1, a ligand for the TIE2 receptor, during embryonic
angiogenesis. Cell. 87:1171–1180. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jones N, Iljin K, Dumont DJ and Alitalo K:
The receptors: New modulators of angiogenic and lymphangiogenic
responses. Nat Rev Mol Cell Biol. 2:257–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ferrara N, Geber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dickson MC, Martin JS, Cousins FM,
Kulkarni AB, Karlsson S and Akhurst RJ: Defective haematopoiesis
and vasculogenesis in transforming growth factor-beta 1 knock out
mice. Development. 121:1845–1854. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Larsson J, Goumans MJ, Sjőstrand LJ, van
Rooijen MA, Levéen P, Xu X, ten Dijke P, Mummery CL and Karlsson S:
Abnormal angiogenesis but intact hematopoietic potential in
TGF-beta type I receptor-deficient mice. EMBO J. 20:1663–1673.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hamada K, Sasaki T, Koni PA, Natsui M,
Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, et
al: The PTEN/PI3K pathway governs normal vascular development and
tumor angiogenesis. Genes Dev. 19:2054–2065. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qin J, Chen X, Yu-Lee L, Tsai MJ and Tsai
SY: Nuclear receptor COUP-TFII controls pancreatic islet tumor
angiogenesis by regulating VEGF/VEGFR-2 signaling. Cancer Res.
70:8812–8821. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dougherty EJ, Chen LY, Awad KS, Ferreyra
GA, Demirkale CY, Keshavarz A, Gairhe S, Johnston KA, Hicks ME,
Sandler AB, et al: Inflammation and DKK1-induced AKT activation
contribute to endothelial dysfunction following NR2F2 loss. Am J
Physiol Lung Cell Mol Physiol. 324:L783–L798. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cao Y, Zhang X, Wang L, Yang Q, Ma Q, Xu
J, Wang J, Kovacs L, Ayon RJ, Liu Z, et al: PFKEB3-mediated
endothelial glycolysis promotes pulmonary hypertension. Proc Natl
Acad Sci USA. 116:13394–13403. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Talati M and Hemnes A: Fatty acid
metabolism in pulmonary arterial hypertension: Role in right
ventricular dysfunction and hypertrophy. Pulm Circ. 5:269–278.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
59
|
Poels K, Schnitzler JG, Waissi F, Levels
JHM, Stroes ESG, Daemen MJAP, Lutgens E, Pennekamp AM, De Kleijin
DPV, Seijkens TTP and Kroon J: Inhibition of PFKFB3 hampers the
progression of atherosclerosis and promotes plaque stability. Front
Cell Dev Biol. 8:5816412020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rodríguez-García A, Samsó P, Fontova P,
Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U,
Ventura F, Navarro-Sabaté À and Bartrons R: TGF-β1 targets Smad,
p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene
expression and glycolysis in glioblastoma cells. FEBS J.
284:3437–3454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nakamura E, Makita Y, Okamoto T, Nagaya K,
Hayashi T, Sugimoto M, Manabe H, Taketazu G, Kajino H and Fujieda
K: 5.78 Mb terminal deletion of chromosome 15q in a girl,
evaluation of NR2F2 as candidate gene for congenital heart defects.
Eur J Med Genet. 54:354–356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Qiao XH, Wang Q, Wang J, Liu XY, Xu YJ,
Huang RT, Xue S, Li YJ, Zhang M, Qu XK, et al: A novel NR2F2
loss-of-function mutation predisposes to congenital heart defect.
Eur J Med Genet. 61:197–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Upadia J, Gonzales PR and Robin NH: Novel
de novo pathogenic variant in the NR2F2 gene in a boy with
congenital heart defect and dysmorphic features. Am J Med Genet A.
176:1423–1426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cornea A, Gilboa SM, Besser LM, Botto LD,
Moore CA, Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK and
Reece EA: Diabetes mellitus and birth defects. Am J Obstet Gynecol.
199:e1–e9. 2008.
|
|
65
|
Botto LD, Loffredo C, Scanlon KS, Ferencz
C, Khoury MJ, David Wilson P and Correa A: Vitamin A and cardiac
outflow tract defects. Epidemiology. 12:491–496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Perilhou A, Tourrel-Cuzin C, Kharroubi I,
Henique C, Fauveau V, Kitamura T, Magnan C, Posric C, Prip-Buus C
and Vasseur-Cognet M: The transcription factor COUP-TFII is
negatively regulated by insulin and glucose via Foxo1- and
ChREBP-controlled pathways. Mol Cell Biol. 28:6568–6579. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vilhais-Neto GC, Maruhashi M, Smith KT,
Vasseur-Cognet M, Peterson AS, Workman JI and Pourquié O: Rere
controls retinoic acid signaling and somite bilateral symmetry.
Nature. 463:953–957. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gruber PJ and Epstein JA: Developmental
gone awry. Congenital heart disease. Cir Res. 94:273–283. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wu SP, Kao CY, Wang L, Creighton CJ, Yang
J, Donti TR, Harmancey R, Vasquez HG, Graham BH, Bellen HJ, et al:
Increased COUP-TFII expression in adult hearts induces
mitochondrial dysfunction resulting in heart failure. Nat Commun.
6:82452015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kittleson MM, Minhas KM, Irizarry RA, Ye
SQ, Edness G, Breton E, Conte JV, Tomaselli G, Garcia JG and Hare
JM: Gene expression analysis of ischemic and nonischemic
cardiomyopathy: Shared and distinct genes in the development of
heart failure. Physiol Genomics. 21:299–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hannenhalli S, Putt ME, Gilmore JM, Wang
J, Parmacek MS, Epstein JA, Morrisey EE, Margulies KB and Cappola
TP: Transcriptional genomics associates FOX transcription factors
with human heart failure. Circulation. 114:1269–1276. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Miao W, Chen M, Chen M, Cui C, Zhu Y, Luo
X and Wu B: Nr2f2 overexpression aggravates ferroptosis and
mitochondrial dysfunction by regulating PGC-1α signaling in
diabetes-induced heart failure mice. Mediators Inflamm.
2022:83733892022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tan Y, Zhang Z, Zheng C, Wintergerst KA,
Keller BB and Cai L: Mechanisms of diabetic cardiomyopathy and
potential therapeutic strategies: Preclinical and clinical
evidence. Nat Rev Cardiol. 17:585–607. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Dhalla NS, Shah AK and Tappia PS: Role of
oxidative stress in metabolic and subcellular abnormalities in
diabetic cardiomyopathy. Int J Mol Sci. 21:24132020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferrptosis, an iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li W, Li W, Leng Y, Xiong Y and Xia Z:
Ferroptosis is involved in diabetes myocardial ischemia/reperfusion
injury through endoplasmic reticulum stress. DNA Cell Biol.
39:210–225. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ma S, Sun L, Wu W, Wu J, Sun Z and Ren J:
USP22 protects against myocardial ischemia-reperfusion injury via
the SIRT-p53/SLC7A11-dependent inhibition of ferroptosis-induced
cardiomyocyte death. Front Physiol. 11:5513182020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tang LJ, Zhou YJ, Xiong XM, Li NS, Zhang
JJ, Luo XJ and Peng J: Ubiquitin-specific protease 7 promotes
ferroptosis via activation of the p53/TfR1 pathway in the rat
hearts after ischemia/reperfusion. Free Rad Biol Med. 162:339–352.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang X, Chen X, Zhou W, Men H, Bao T, Sun
Y, Wang Q, Tan Y, Keller BB, Tong Q, et al: Ferroptosis is
essential for diabetic cardiomyopathy and is prevented by
sulforaphane via AMPK/NRF2 pathways. Acta Phama Sin B. 12:708–722.
2022. View Article : Google Scholar
|
|
80
|
Shin SW, Kwon HC, Rho MS, Choi HJ, Kwak JY
and Park JI: Clinical significance of chicken ovalbumin upstream
promoter-transcription factor II expression in human colorectal
cancer. Oncol Rep. 21:101–106. 2009.PubMed/NCBI
|
|
81
|
Yun SH, Park MG, Kim YM, Roh MS and Park
JI: Expression of chicken ovalbumin upstream promoter-transcription
factor II and liver X receptor as prognostic indicators for human
colorectal cancer. Oncol Lett. 14:4011–4020. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yun SH and Park JI: COUP-TFII
overexpression inhibits cell proliferation and invasion via
increased expression of p53 and PTEN and decreased Akt
phosphorylation in human colorectal cancer SNU-C4 cells. Anticancer
Res. 40:767–777. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yun SH, Han SH and Park JI: COUP-TFII
knock-down promotes proliferation and invasion in colorectal cancer
cells via activation of Akt pathway and up-regulation of FOXC1.
Anticancer Res. 40:177–190. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Bao Y, Gu D, Feng W, Sun X, Wang X, Zhang
X, Shi Q, Cui G, Yu H, Tang C and Deng A: COUP-TFII regulates
metastasis of colorectal adenocarcinoma cells by modulating Snail1.
Br J Cancer. 111:933–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang C, Zhou Y, Ruan R, Zheng M, Han W and
Liao L: High expression of COUP-TFII cooperated with negative Smad4
expression predicts poor prognosis in patients with colorectal
cancer. Int J Clin Exp Pathol. 8:7112–7121. 2015.PubMed/NCBI
|
|
86
|
Cano A, Pérez-Moreno MA, Rodrigo I, Blanco
MJ, del Barrio MG, Portillo F and Nieto MA: The transcription
factor snail controls epithelial-mesenchymal transitions by
repressing E-cadherin expression. Nat Cell Biol. 2:76–83. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li X, Deng W, Lobo-Ruppert SM and Ruppert
JM: Gli1 acts through Snail and E-cadherin to promote nuclear
signaling by beta-catenin. Oncogene. 26:4489–4498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pfeffer SR, Yang CH and Pfeffer LM: The
role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang H, Nie L, Wu L, Liu Q and Guo X:
NR2F2 inhibits Smad7 expression and promotes TGF-β-dependent
epithelial-mesenchymal transition of CRC via transactivation of
miR-21. Biochem Biophys Res Commun. 485:181–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bao Y, Lu Y, Feng W, Yu H, Guo H, Tao Y,
Shi Q, Chen W and Wang X: COUP-TFII promotes epithelial-mesenchymal
transition by inhibiting miR-34a expression in colorectal cancer.
Int J Oncol. 54:1337–1344. 2019.PubMed/NCBI
|
|
92
|
Zhang D, Qiu X, Li J, Zheng S, Li L and
Zhao H: TGF-β secreted by tumor-associated macrophages promotes
proliferation and invasion of colorectal cancer via miR-34a-VEGF
axis. Cell Cycle. 17:2766–2778. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu
MH and Zhong M: Long non-coding RNA NEAT1 promotes colorectal
cancer progression by competitively binding miR-34a with SIRT1 and
enhancing the Wnt/β-catenin signaling pathway. Cancer Lett.
440–441. 11–22. 2019.
|
|
94
|
Li Y, Gong P, Hou JX, Huang W, Ma XP, Wang
YL, Li J, Cui XB and Li N: miR-34a regulates multidrug resistance
via positively modulating OAZ2 signaling in colon cancer cells. J
Immunol Res. 2018:74985142018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wu QB, Sheng X, Zhang N, Yang MW and Wang
F: Role of microRNAs in the resistance of colorectal cancer to
chemoradiotherapy. Mol Clin Oncol. 8:523–527. 2018.PubMed/NCBI
|
|
96
|
Li X, Large MJ, Creighton CJ, Lanz RB,
Jeong JW, Young SL, Lessey BA, Palomino WA, Tsai SY and DeMayo FJ:
COUP-TFII regulates human endometrial stromal genes involved in
inflammation. Mol Endocrinol. 27:2041–2054. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
|
|
98
|
Niederseer D, Stadlmayr A, Huber-Schőnauer
U, Plöderl M, Schmied C, Lederer D, Patsch W, Aigner E and Datz C:
Cardiovascular risk and known coronary artery disease are
associated with colorectal adenoma and advanced neoplasia. J Am
Coll Cardiol. 69:2348–2350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Erichsen R, Sværke C, Sørensen HT, Sandler
RS and Baron JA: Risk of colorectal cancer in patients with acute
myocardial infarction and stroke: A nationwide cohort study. Cancer
Epidemiol Biomarkers Prev. 22:1994–1999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Meijers WC, Maglione M, Bakker SJL,
Oberhuber R, Kieneker LM, de Jong S, Haubener BJ, Nagengast WB,
Lyon AR, van der Vegt B, et al: Heart failure stimulates tumor
growth by circulating factors. Circulation. 138:678–691. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Dai YN, Wang JH, Zhu JZ, Lin JQ, Yu CH and
Li YM: Angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers therapy and colorectal cancer: A systematic
review and meta-analysis. Cancer Causes Control. 26:1245–1255.
2015.PubMed/NCBI
|
|
102
|
Chen X, Yi CH and Ya KG: Renin-angiotensin
system inhibitor use and colorectal cancer risk and mortality: A
dose-response meta analysis. J Renin Angiotensin Aldosterone Syst.
Jul 6–2020.(Epub ahead of print). View Article : Google Scholar
|
|
103
|
Koene RJ, Prizment AE, Blaes A and Konety
SH: Shared risk factors in cardiovascular disease and cancer.
Circulation. 133:1104–1114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhang C, Cheng Y, Luo D, Wang J, Liu J,
Luo Y, Zhou W, Zhuo Z, Guo K, Zeng R, et al: Association between
cardiovascular risk factors and colorectal cancer: A systematic
review and meta-analysis of prospective cohort studies.
eClinicalMedicine. 34:1007942021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Bertero E, Canepa M, Maack C and Ameri P:
Linking heart failure to cancer: Background evidence and research
perspectives. Circulation. 138:735–742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Amker
SD, et al: Antiinflammatory therapy with canakinumab for
atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Prizment AE, Folsom AR, Dreyfus J,
Anderson KE, Visvanathan K, Joshu CE, Platz EA and Pankow JS:
Plasma C-reactive protein, genetic risk score, and risk of common
cancers in the atherosclerosis risk in communities study. Cancer
Causes Control. 24:2077–2087. 2013.PubMed/NCBI
|
|
108
|
Qu D, Shen L, Liu S, Li H, Ma Y, Zhang R,
Wu K, Yao L, Li J and Zhang J: Chronic inflammation confers to the
metabolic reprogramming associated with tumorigenesis of colorectal
cancer. Cance Biol Ther. 18:237–244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yang L, Fang C, Zhang R and Zhou S:
Prognostic value of oxidative stress-related genes in colorectal
cancer and its correlation with tumor immunity. BMC Genomics.
25:82024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kannan RY, Salacinski HJ, Butler PE,
Hamilton G and Seifalian AM: Current status of prosthetic bypass
grafts: A review. J Biomed Mater Res B Appl Biomater. 74:570–581.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Goncalves RC, Banfi A, Oliveira MB and
Mano JF: Strategies for re-vascularization and promotion of
angiogenesis in trauma and disease. Biomaterials. 269:1206282021.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kirkton RD, Santiago-Maysonet M, Lawson
JH, Tente WE, Dahl SLM, Niklason LE and Prichard HL: Bioengineered
human acellular vessels recellularize and evolve into living blood
vessels after human implantation. Sci Transl Med. 11:eaau69342019.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lin RZ, Im GB, Luo AC, Zhu Y, Hong X,
Neumeyer J, Tang HW, Perrimon N and Melero-Martin JM: Mitochondrial
transfer mediates endothelial cell engraftment through mitophagy.
Nature. 629:660–668. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Xing M, Wang F, Chu R, Wang H, Sun Y, Qian
M, Jiang H, Midgley AC, Dai G and Zhao Q: Localized COUP-TFII pDNA
delivery modulates stem/progenitor cell differentiation to enhance
endothelialization and inhibit calcification of decellularized
allografts. Adv Sci (Weinh). 12:e24097442025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang L, Cheng CM, Qin J, Xu M, Kao CY, Shi
J, You E, Gong W, Rosa LP, Chase P, et al: Small-molecule inhibitor
targeting orphan nuclear receptor COUP-TFII for prostate cancer
treatment. Sci Adv. 6:eaaz80312020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Wang F, Zhang S, Sun F, Chen W, Liu C,
Dong H, Cui B, Li L, Sun C, Du W, et al: Anti-angiogenesis and
anti-immunosuppression gene therapy through targeting COUP-TFII in
an in situ glioblastoma mouse model. Cancer Gene Ther.
31:1135–1150. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lin B, Chen GQ, Xiao D, Kollori SK, Cao X,
Su H and Zhang XK: Orphan receptor COUP-TF is required for
induction of retinoic acid receptor beta, growth inhibition, and
apoptosis by retinoic acid in cancer cells. Mol Cell Biol.
20:957–970. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang X, Jiang R, Cui E, Feng W, Guo H, Gu
D, Tang C, Xue T and Bao Y: COUP-TFII suppresses colorectal
carcinoma resistance to doxorubicin involving inhibition of
epithelial-mesenchymal transition (corrected). Am J Transl Res.
8:3921–3929. 2016.PubMed/NCBI
|
